Business Wire

2015, a Strategic Year for LFB


Key events in 2015 :

  • Launched a new generation plant financed by a €230 million capital increase, fully underwritten by the French State, currently the sole shareholder of LFB.
  • Two new products registered in Europe
  • Significant investment in R&D with €81.3 million* owing to several products currently in phase III trials
  • Gross margin in decline as compared to 2014 due to the production of commercial batches for phase III products
  • Turnover of €502.4 million, stable in comparison to 2014

Christian Béchon, Chief Executive Officer of L.F.B S.A. declared:
"In 2015, the key milestones have been successfully achieved. It has been a historic and productive year for the future of LFB."

An unprecedented increase in capital in order to finance the group's development
As part of the group's strategic development, LFB's shareholder (the French State) decided in October to underwrite an increase in LFB's share capital by €230 million. The share capital of the company now stands at €280 million. To meet the financing needs of LFB's development project, on 5 January 2016 LFB issued a senior bond of €124 million. These funds will enable the construction of a 'new generation' plant in Arras. This flagship project, representing an investment of approximately €300 million, will enable LFB to triple its global production capacity in 2020 with facilities aimed at manufacturing for the whole world.
LFB is also developing its sites in Alès (Gard) and Charlton (USA), establishing bio-production facilities for recombinant medicines in development.

Consolidated earnings in €M

  2015   2014   Variation 2015/2014







0.1 %

Gross margin






-9.2 %

Research & development






Commercial costs






General costs






Other charges and
operational income






Operational earnings






as a % of turnover


2.4 %


5.0 %


Net earnings




€90.5 million* before research tax credit

2015 turnover - growth in international sales
At €502.4 million, turnover is relatively stable as compared to 2014. For the second successive year, the group's turnover exceeded €500 million, with the international side business continuing to grow. Despite a 3.2 % decline in turnover in France during 2015, international sales rose by €12.1 million (+8.7%), reaching €152 million. This figure represents 30% of consolidated turnover (28% in 2014).

Operational earnings decline in order to finance strategy
Research and development costs are increasing rapidly (€81.3 million), owing to the large number of phase III trials in progress. Various strategic projects reached significant milestones. In 2015, two new LFB products, a 10% immunoglobulin and a fibrinogen have been subject to a mutual recognition in procedure in Europe with the Paul Ehrlich Institute as the referral agency. Two other recombinant products are currently at the end of phase III. At the same time, LFB is planning to manufacture product batches for launch, which has had an impact on earnings. In 2015, the group posted encouraging operational income (€17 million), notably owing to its holding in the bio-tech company TG Therapeutics Inc. The positive operational earnings (€12.0 million) is down as compared to that of 2014 (-13.2 million) due to a decline in gross margins and increased development costs. Despite this unprecedented effort, net earnings remain positive at €0.3 million.

About LFB Group
LFB is a bio-pharmaceutical company that develops, manufactures, and markets medicinal products from living systems for the treatment of serious and often rare diseases in the fields of Immunology, Hemostasis, Perinatal, and Intensive Care. Currently ranked 6th worldwide in the field of plasma-derived medicinal products, LFB Group is also among the leading European companies in the development and production of proteins and innovative treatments derived from bio-technologies. It employs 2,111 staff worldwide.

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

Contact information

Sandrine Charrières,
Communication Director
David Loison,
Financial Affairs Director
Havas Worldwide
Jeanne Bariller,

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

More than 70 Companies to Showcase Top Tech at CES Unveiled Paris20.10.2017 15:08Pressemelding

The Consumer Technology Association (CTA) today announced that more than 70 exhibitors will showcase their latest innovations at the now sold-out fifth annual CES Unveiled Paris The event will focus on the Internet of Things (IoT), connectivity and smart cities, and draw more than 600 attendees. CES Unveiled Paris will run from 2-7:30 PM on Tuesday, October 24, 2017 at the Palais Brongniart. Regional technology companies, top-tier media outlets, buyers and key industry influencers will come together at CES Unveiled Paris to get a direct look at the latest industry developments. The day kicks off with a CES news conference and CTA market trends presentation. Conference programming is followed by a tabletop exhibition & networking reception. Curated exhibitors will be there to showcase top tech from robotics and audio to smart home and augmented and virtual reality. Notable

Westinghouse Receives Regulatory Approval for Analysis Methodologies20.10.2017 12:15Pressemelding

Westinghouse Electric Company today announced that it has received approval from the U.S. Nuclear Regulatory Commission (NRC) for two new important analysis methodologies that will be used to upgrade Westinghouse- and Combustion Engineering-based nuclear steam supply system (NSSS) safety analyses. The approvals granted are for the new FULL SPECTRUMTM Loss of Coolant Accident (FSLOCATM) methodology and the Performance Analysis and Design Model software code update, PAD5. FSLOCA is capable of improved modeling of the transient response in a pressurized water reactor to the full spectrum of LOCA break sizes that could occur, and PAD5 is the next generation of the Westinghouse fuel rod design performance code. “These codes were developed to work in concert with each other to maximize analytical margin for nuclear utilities,” said Michele DeWitt, senior vice preside

Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread®20.10.2017 12:03Pressemelding

Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from Phase 2 and Phase 3 studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead’s viral hepatitis therapies in diverse patient populations. These and other data from more than 25 abstracts will be presented this week at The Liver Meeting® 2017, which begins today in Washington, D.C. Positive results from studies of Harvoni® (ledipasvir 90mg/sofosbuvir 400mg) in HCV-infected patients with severe renal impairment, Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) in HCV-infected liver transplant recipients and Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg) in NS5A-inhibitor experienced HCV-infected patients will be presented during poster sessions on October 21 and October 22. In addition, updated results f

SP3H Announces That It Has Obtained a €1.2 Million European Union Grant for Its Intelligent and Clean Vehicle (VIP) Project20.10.2017 10:47Pressemelding

SP3H is proud to announce joining the very select circle of the 10 French winners of the H2020 SME Instrument Phase 2 program since 2014. This press release features multimedia. View the full release here: Last summer VIP received the very prestigious SME instrument phase 2 H2020 label in the "transport & smart cities mobility" category. With an overall budget of € 1.7 million, VIP is subsidized by the European Union at a rate of 70% or €1.2 million. The framework contract was officially signed early October. VIP is the pre-industrialization program for Fuelbox sensors, the world's first miniaturized scanner capable of analyzing the quality of fuels on board vehicles. The heart of the program remains closely linked to the reduction of CO2 and pollutant emissions from vehicle

Kennedy Wilson and Kennedy Wilson Europe Real Estate Plc Complete Merger, Creating $8 Billion Global Real Estate Company20.10.2017 10:00Pressemelding

Global real estate investment company Kennedy-Wilson Holdings, Inc. (NYSE:KW) (“KW”) today announced the completion of its merger with Kennedy Wilson Europe Real Estate Plc (LSE:KWE) (“KWE”). The transaction creates a leading global real estate investment and asset management platform with an $8 billion enterprise value. “This transformative combination with KWE represents an exciting new chapter for our company,” said William J. McMorrow, Chairman and CEO of KW. “We are moving towards a simplified corporate structure that provides more recurring income from stable property cash flows and greater upside potential from value-enhancing initiatives worldwide. We are well positioned for future growth and to continue our track record of generating attractive risk-adjusted returns on our invested capital.” “We are thrilled to combine the financial strength of KW and KWE to continu

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom